JNJ Stock Analysis: Johnson & Johnson | NYSE
Drug Manufacturers - General | NYSE, USA | Market Cap: 623.344m USD | 12M Return: 39.9% | US4781601046 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 1.69B
EPS Trend: 32.9%
Qual. Beats: 0
Rev. Trend: 94.3%
Qual. Beats: 3
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Johnson & Johnson (NYSE: JNJ) is a diversified U.S.-based healthcare conglomerate that researches, develops, manufactures, and sells products globally through two main segments: Innovative Medicine, which focuses on prescription pharmaceuticals across therapeutic areas such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular/metabolic conditions; and MedTech, which supplies medical devices and technologies in surgery, orthopedics, cardiovascular care, and vision (including ACUVUE contact lenses and TECNIS intraocular lenses), serving surgeons, hospitals, eye-care professionals, and clinics. The company distributes through retailers, wholesalers, hospitals, and healthcare professionals, and is headquartered in New Brunswick, New Jersey, having been founded in 1886 and listed since 1944. As a mega-cap stock classified within the GICS Health Care sector (Pharmaceuticals sub-industry), JNJ operates one of the few remaining large-scale models that combines a global pharmaceutical franchise with a substantial medical devices business under a single corporate umbrella, following the 2023 separation of its consumer health operations into a standalone company.
- Stelara biosimilar competition threatens Innovative Medicine revenue
- Oncology franchise led by Darzalex accelerates pharmaceutical sales growth
- Talc litigation settlements and reserves pressure profit margins
| Net Income: 21.0b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 0.82 > 1.0 |
| NWC/Revenue: 4.98% < 20% (prev 0.35%; Δ 4.63% < -1%) |
| CFO/TA 0.12 > 3% & CFO 23.7b > Net Income 21.0b |
| Net Debt (28.3b) to EBITDA (33.7b): 0.84 < 3 |
| Current Ratio: 1.09 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.44b) vs 12m ago 0.87% < -2% |
| Gross Margin: 67.91% > 18% (prev 67.92%; Δ -0.01% > 0.5%) |
| Asset Turnover: 49.65% > 50% (prev 46.86%; Δ 2.79% > 0%) |
| Interest Coverage Ratio: 25.67 > 6 (EBIT TTM 26.0b / Interest Expense TTM 1.01b) |
| A: 0.02 (Total Current Assets 59.8b - Total Current Liabilities 54.9b) / Total Assets 201b |
| B: 0.85 (Retained Earnings 172b / Total Assets 201b) |
| C: 0.13 (EBIT TTM 26.0b / Avg Total Assets 197b) |
| D: 0.73 (Book Value of Equity 85.0b / Total Liabilities 116b) |
| Altman-Z'' = 4.60 = AA |
| DSRI: 0.99 (Receivables 19.0b/17.8b, Revenue 97.9b/90.6b) |
| GMI: 1.00 (GM 67.92% / 67.91%) |
| AQI: 0.97 (AQ_t 0.59 / AQ_t-1 0.60) |
| SGI: 1.08 (Revenue 97.9b / 90.6b) |
| TATA: -0.01 (NI 21.0b - CFO 23.7b) / TA 201b) |
| Beneish M = -3.00 (Cap -4..+1) = A |
As of October 10, 2026, the stock is trading at USD 261.44 with a total of 5,460,176 shares traded. Over the past week, the price has changed by +2.11%, over one month by -2.11%, over three months by +1.40% and over the past year by +39.92%.
Current recommended Stop Loss: 254.40 (which is 2.7% or 1.4 ATR below the current price).
Johnson & Johnson has received a consensus analysts rating of 4.09. Therefore, it is recommended to buy JNJ.
- StrongBuy: 11
- Buy: 5
- Hold: 6
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 279.3 | 6.8% |
P/E Trailing = 30.6833
P/E Forward = 21.0084
P/S = 6.3653
P/B = 7.6346
P/EG = 2.8229
Revenue TTM = 97.9b USD
EBIT TTM = 26.0b USD
EBITDA TTM = 33.7b USD
Long Term Debt = 37.3b USD (from longTermDebt, last quarter)
Short Term Debt = 11.7b USD (from shortTermDebt, last quarter)
Debt = 49.0b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 28.3b USD (calculated: Debt 49.0b - CCE 20.8b)
Enterprise Value = 652b USD (623b + Debt 49.0b - CCE 20.8b)
Interest Coverage Ratio = 25.67 (Ebit TTM 26.0b / Interest Expense TTM 1.01b)
EV/FCF = 34.83x (Enterprise Value 652b / FCF TTM 18.7b)
FCF Yield = 2.87% (FCF TTM 18.7b / Enterprise Value 652b)
FCF Margin = 19.10% (FCF TTM 18.7b / Revenue TTM 97.9b)
Net Margin = 21.48% (Net Income TTM 21.0b / Revenue TTM 97.9b)
Gross Margin = 67.91% ((Revenue TTM 97.9b - Cost of Revenue TTM 31.4b) / Revenue TTM)
Gross Margin QoQ = 68.19% (prev 66.31%)
Tobins Q-Ratio = 3.24 (Enterprise Value 652b / Total Assets 201b)
Interest Expense / Debt = 2.06% (Interest Expense 1.01b / Debt 49.0b)
Taxrate = 16.51% (4.16b / 25.2b)
NOPAT = 21.7b (EBIT 26.0b * (1 - 16.51%))
Current Ratio = 1.09 (Total Current Assets 59.8b / Total Current Liabilities 54.9b)
Debt / Equity = 0.58 (Debt 49.0b / totalStockholderEquity, last quarter 85.0b)
Debt / EBITDA = 0.84 (Net Debt 28.3b / EBITDA 33.7b)
Debt / FCF = 1.51 (Net Debt 28.3b / FCF TTM 18.7b)
Total Stockholder Equity = 81.7b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.67% (Net Income 21.0b / Total Assets 201b)
RoE = 25.74% (Net Income TTM 21.0b / Total Stockholder Equity 81.7b)
RoCE = 21.82% (EBIT 26.0b / Capital Employed (Equity 81.7b + L.T.Debt 37.3b))
RoIC = 14.18% (NOPAT 21.7b / Invested Capital 153b)
WACC = 4.53% (E(623b)/V(672b) * Re(4.75%) + D(49.0b)/V(672b) * Rd(2.06%) * (1-Tc(0.17)))
Discount Rate = 4.75% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 66.48 | Cagr: 0.18%
[DCF] Terminal Value 77.81% ; FCFF base≈17.8b ; Y1≈20.2b ; Y5≈29.1b
[DCF] Fair Price = 170.4 (EV 439b - Net Debt 28.3b = Equity 411b / Shares 2.41b; r=8.35% [WACC [floored]]; 5y FCF grow 14.00% → 2.50% )
EPS Correlation: 32.91 | EPS CAGR: 1.05% | SUE: 0.75 | # QB: 0
Revenue Correlation: 94.35 | Revenue CAGR: 4.92% | SUE: 0.98 | # QB: 3
EPS current Quarter (2026-09-30): EPS=2.48 | Chg30d=+2.33% | Revisions=+0% | Analysts=8
EPS current Year (2026-12-31): EPS=11.08 | Chg30d=+0.26% | Revisions=+0% | GrowthEPS=+2.7% | GrowthRev=+7.5%
EPS next Year (2027-12-31): EPS=12.00 | Chg30d=-2.53% | Revisions=+0% | GrowthEPS=+8.3% | GrowthRev=+7.3%
[Analyst] Revisions Ratio: +0% (up=0, down=0)